Schedule 13G ownership disclosure
BIOCRYST PHARMACEUTICALS INC
Common Stock, $0.01 par value · CUSIP: 09058V103
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Avoro Capital Advisors LLC
Shares: 8,700,000.00 · Class: 4.2%
- Behzad Aghazadeh
Shares: 8,700,000.00 · Class: 4.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-002355
- Form type
- SCHEDULE 13G/A
- Filer
- Avoro Capital Advisors LLC
- CIK
- CIK 1633313
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership